2g9c: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
==Modified pyrimidines Specifically bind the purine riboswitch== | ==Modified pyrimidines Specifically bind the purine riboswitch== | ||
<StructureSection load='2g9c' size='340' side='right' caption='[[2g9c]], [[Resolution|resolution]] 1.70Å' scene=''> | <StructureSection load='2g9c' size='340' side='right' caption='[[2g9c]], [[Resolution|resolution]] 1.70Å' scene=''> | ||
Line 4: | Line 5: | ||
<table><tr><td colspan='2'>[[2g9c]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2G9C OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2G9C FirstGlance]. <br> | <table><tr><td colspan='2'>[[2g9c]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2G9C OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2G9C FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=3AY:PYRIMIDINE-2,4,6-TRIAMINE'>3AY</scene>, <scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=NCO:COBALT+HEXAMMINE(III)'>NCO</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=3AY:PYRIMIDINE-2,4,6-TRIAMINE'>3AY</scene>, <scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=NCO:COBALT+HEXAMMINE(III)'>NCO</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2g9c FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2g9c OCA], [http://pdbe.org/2g9c PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=2g9c RCSB], [http://www.ebi.ac.uk/pdbsum/2g9c PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2g9c FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2g9c OCA], [http://pdbe.org/2g9c PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=2g9c RCSB], [http://www.ebi.ac.uk/pdbsum/2g9c PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=2g9c ProSAT]</span></td></tr> | ||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> |
Revision as of 10:49, 18 October 2017
Modified pyrimidines Specifically bind the purine riboswitchModified pyrimidines Specifically bind the purine riboswitch
Structural highlights
Publication Abstract from PubMedThe purine riboswitch is a genetic regulatory element found in the 5'-untranslated regions of Gram-positive bacteria that regulates expression of the mRNA specifically in response to either guanine or adenine. We report that the adenine-responsive RNA element is also capable of specifically recognizing pyrimidine compounds bearing modifications at the 6- or 5,6-positions in a fashion similar to that of purine compounds. Using isothermal titration calorimetry and X-ray crystallography, the binding of these compounds is characterized. Modified pyrimidines specifically bind the purine riboswitch.,Gilbert SD, Mediatore SJ, Batey RT J Am Chem Soc. 2006 Nov 8;128(44):14214-5. PMID:17076468[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
|